Literature DB >> 22349092

Spectral confocal imaging of fluorescently tagged nicotinic receptors in knock-in mice with chronic nicotine administration.

Anthony Renda1, Raad Nashmi.   

Abstract

Ligand-gated ion channels in the central nervous system (CNS) are implicated in numerous conditions with serious medical and social consequences. For instance, addiction to nicotine via tobacco smoking is a leading cause of premature death worldwide (World Health Organization) and is likely caused by an alteration of ion channel distribution in the brain. Chronic nicotine exposure in both rodents and humans results in increased numbers of nicotinic acetylcholine receptors (nAChRs) in brain tissue. Similarly, alterations in the glutamatergic GluN1 or GluA1 channels have been implicated in triggering sensitization to other addictive drugs such as cocaine, amphetamines and opiates. Consequently, the ability to map and quantify distribution and expression patterns of specific ion channels is critically important to understanding the mechanisms of addiction. The study of brain region-specific effects of individual drugs was advanced by the advent of techniques such as radioactive ligands. However, the low spatial resolution of radioactive ligand binding prevents the ability to quantify ligand-gated ion channels in specific subtypes of neurons. Genetically encoded fluorescent reporters, such as green fluorescent protein (GFP) and its many color variants, have revolutionized the field of biology. By genetically tagging a fluorescent reporter to an endogenous protein one can visualize proteins in vivo. One advantage of fluorescently tagging proteins with a probe is the elimination of antibody use, which have issues of nonspecificity and accessibility to the target protein. We have used this strategy to fluorescently label nAChRs, which enabled the study of receptor assembly using Förster Resonance Energy Transfer (FRET) in transfected cultured cells. More recently, we have used the knock-in approach to engineer mice with yellow fluorescent protein tagged α4 nAChR subunits (α4YFP), enabling precise quantification of the receptor ex vivo at submicrometer resolution in CNS neurons via spectral confocal microscopy. The targeted fluorescent knock-in mutation is incorporated in the endogenous locus and under control of its native promoter, producing normal levels of expression and regulation of the receptor when compared to untagged receptors in wildtype mice. This knock-in approach can be extended to fluorescently tag other ion channels and offers a powerful approach of visualizing and quantifying receptors in the CNS. In this paper we describe a methodology to quantify changes in nAChR expression in specific CNS neurons after exposure to chronic nicotine. Our methods include mini-osmotic pump implantation, intracardiac perfusion fixation, imaging and analysis of fluorescently tagged nicotinic receptor subunits from α4YFP knock-in mice (Fig. 1). We have optimized the fixation technique to minimize autofluorescence from fixed brain tissue. We describe in detail our imaging methodology using a spectral confocal microscope in conjunction with a linear spectral unmixing algorithm to subtract autofluoresent signal in order to accurately obtain α4YFP fluorescence signal. Finally, we show results of chronic nicotine-induced upregulation of α4YFP receptors in the medial perforant path of the hippocampus.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349092      PMCID: PMC3415205          DOI: 10.3791/3516

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  30 in total

Review 1.  Why doesn't nicotinic ACh receptor immunoreactivity knock out?

Authors:  Ian W Jones; Susan Wonnacott
Journal:  Trends Neurosci       Date:  2005-07       Impact factor: 13.837

Review 2.  The Nikon C1si combines high spectral resolution, high sensitivity, and high acquisition speed.

Authors:  Jeffrey M Larson
Journal:  Cytometry A       Date:  2006-08-01       Impact factor: 4.355

3.  Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path.

Authors:  Raad Nashmi; Cheng Xiao; Purnima Deshpande; Sheri McKinney; Sharon R Grady; Paul Whiteaker; Qi Huang; Tristan McClure-Begley; Jon M Lindstrom; Cesar Labarca; Allan C Collins; Michael J Marks; Henry A Lester
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

4.  Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures.

Authors:  N Moser; N Mechawar; I Jones; A Gochberg-Sarver; A Orr-Urtreger; M Plomann; R Salas; B Molles; L Marubio; U Roth; U Maskos; U Winzer-Serhan; J-P Bourgeois; A-M Le Sourd; M De Biasi; H Schröder; J Lindstrom; A Maelicke; J-P Changeux; A Wevers
Journal:  J Neurochem       Date:  2007-04-10       Impact factor: 5.372

Review 5.  The green fluorescent protein.

Authors:  R Y Tsien
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

6.  Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine.

Authors:  M R Picciotto; M Zoli; R Rimondini; C Léna; L M Marubio; E M Pich; K Fuxe; J P Changeux
Journal:  Nature       Date:  1998-01-08       Impact factor: 49.962

7.  Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors.

Authors:  U Maskos; B E Molles; S Pons; M Besson; B P Guiard; J-P Guilloux; A Evrard; P Cazala; A Cormier; M Mameli-Engvall; N Dufour; I Cloëz-Tayarani; A-P Bemelmans; J Mallet; A M Gardier; V David; P Faure; S Granon; J-P Changeux
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

8.  Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies.

Authors:  D C Perry; M I Dávila-García; C A Stockmeier; K J Kellar
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

9.  Immunolabeling demonstrates the interdependence of mouse brain alpha4 and beta2 nicotinic acetylcholine receptor subunit expression.

Authors:  Paul Whiteaker; John F Cooper; Outi Salminen; Michael J Marks; Tristan D McClure-Begley; Robert W B Brown; Allan C Collins; Jon M Lindstrom
Journal:  J Comp Neurol       Date:  2006-12-20       Impact factor: 3.215

Review 10.  Guidelines on nicotine dose selection for in vivo research.

Authors:  Shannon G Matta; David J Balfour; Neal L Benowitz; R Thomas Boyd; Jerry J Buccafusco; Anthony R Caggiula; Caroline R Craig; Allan C Collins; M Imad Damaj; Eric C Donny; Phillip S Gardiner; Sharon R Grady; Ulrike Heberlein; Sherry S Leonard; Edward D Levin; Ronald J Lukas; Athina Markou; Michael J Marks; Sarah E McCallum; Neeraja Parameswaran; Kenneth A Perkins; Marina R Picciotto; Maryka Quik; Jed E Rose; Adrian Rothenfluh; William R Schafer; Ian P Stolerman; Rachel F Tyndale; Jeanne M Wehner; Jeffrey M Zirger
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

View more
  3 in total

Review 1.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

2.  Development of fluorescence imaging probes for nicotinic acetylcholine α4β2 receptors.

Authors:  Gurleen K Samra; Irakli Intskirveli; Anitha P Govind; Christopher Liang; Ronit Lazar; William N Green; Raju Metherate; Jogeshwar Mukherjee
Journal:  Bioorg Med Chem Lett       Date:  2017-12-17       Impact factor: 2.823

3.  Chronic nicotine pretreatment is sufficient to upregulate α4* nicotinic receptors and increase oral nicotine self-administration in mice.

Authors:  Anthony Renda; Raad Nashmi
Journal:  BMC Neurosci       Date:  2014-07-19       Impact factor: 3.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.